The National Institute for Health and Care Excellence (NICE) has released new draft guidance advising that women living with Polyendocrine Metabolic Ovarian Syndrome (PMOS) should be offered annual health reviews. This proposal, aimed at addressing the long-term systemic health risks of the condition, is currently open for public consultation until 11 August 2026.
Addressing Long-Term Metabolic Risks
Previously known as Polycystic Ovary Syndrome (PCOS), the condition was formally renamed in May 2026 to better reflect the broad spectrum of endocrine and metabolic issues it encompasses. The change, supported by international medical consensus, moves the focus away from reproductive symptoms alone toward broader health concerns such as insulin resistance, type 2 diabetes, and cardiovascular complications that impact an estimated 3 to 4 million women across the United Kingdom.
PMOS is a common but often overlooked condition that can have a major impact on health and wellbeing. Recommending a simple annual review is an important step towards ensuring people get the ongoing care and monitoring they need.
Marieanne Ledingham, consultant clinical advisor for women’s and reproductive health at NICE, stated this during a recent briefing on the draft guidelines. The suggested reviews are intended to provide consistent, proactive monitoring to manage these chronic risks effectively.
Clinical Recommendations And Consultation
The draft guidelines also address current treatment protocols, notably omitting recommendations for laser or light therapies to manage excess hair growth. NICE officials cited a lack of robust clinical evidence regarding the cost-effectiveness of these specific interventions within the public health system.
The consultation period remains active until 11 August 2026, with the final version of the guidelines expected to be published in December 2026. These updates signal a significant shift in the management of PMOS, prioritising integrated primary care oversight to improve patient outcomes over the long term.